Treatment of irritable bowel syndrome: the past, present and future
Abstract
The aim of review. To present data on foreign and Russian clinical studies devoted to improvement of irritable bowel syndrome (IBS) treatment according to the new data on disease pathogenesis.
Summary. Spasmolytics, laxatives or antidiarrheal agents are traditionally applied for treatment of IBS patients according to leading symptom. Considering new data on IBS pathogenesis (disorder of intestinal microbiome, functional and structural remodeling of proteins of cell membrane at the level of synapses of spinal cord posterior horns), prescription of probiotics and peripheral opioid receptors agonists is proven as well. Number of studies, devoted to probiotics efficacy evaluation, is constantly increasing. As a whole, the majority of systematic reviews and metaanalyses draw a conclusion of high efficacy and safety of specified group of drugs at IBS. Agonists of peripheral opioid receptors normalize motility of gastro-intestinal tract and increase a threshold of pain sensitivity mediated by glutamate synaptic receptors of spinal cord posterior horns that prevents development of central and peripheral sensitization. Efficacy of this drug group in IBS patients, also is considered to be proven.
Conclusion. Prescription of probiotics, peripheral opioid receptor agonists at IBS is pathogenicly proven and allows to increase treatment efficacy significantly.
About the Authors
V. T. Ivashkin
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Ye. A. Poluektova
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Poluektova Yelena A – MD, leading research associate, Scientific and educational clinical center of innovative therapy, physician of department of chronic bowel and pancreatic diseases
119991, Moscow, Pogodinskaya street, 1, bld 1
O. S. Lyashenko
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
D. V. Reykhart
State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university», Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
References
1. Всемирная гастроэнтерологическая ассоциация: Практические рекомендации. Пробиотики и пребиотики. Май 2008 г.
2. Гриневич В.Б. Хронический запор. Диагностический алгоритм. Форлакс в лечении хронических запоров при синдроме раздраженной кишки. Рос журн гастроэнтерол гепатол колопроктол 1999; 9(4):84-6.
3. Ивашкин В.Т. Драпкина О.М., Шептулин А.А., Шифрин О.С., Полуэктова Е.А., Кучумова С.Ю. Сравнительная эффективность Флорасана-Д и Резолора в лечении больных с обстипационным вариантом синдрома раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол (в печати).
4. Ивашкин В.Т., Драпкина О.М., Шептулин А.А., Шифрин О.С., Полуэктова Е.А., Кучумова С.Ю. Сравнительная эффективность Флорасана-Д и Энтерола в лечении больных с диарейным вариантом синдрома раздраженного кишечника (в печати).
5. Ивашкин В.Т., Полуэктова Е.А., Белхушет С. Синдром раздраженного кишечника как биопсихосоциальное заболевание. Клин перспективы гастроэнтерол гепатол 2003; 6:2-10.
6. Ивашкин В.Т., Шептулин А.А. Избранные лекции по гастроэнтерологии. М.: МЕДпресс, 2001.
7. Клиническая фармакология по Гудману и Гилману / Под общей ред. А.Г. Гилмана: Пер. с англ. М.: Практика 2006:447-84.
8. Корниенко Е.А. Современные принципы выбора пробиотиков. Детские инфекции 2007; 3:64-9.
9. Материалы четвертой Российской гастроэнтерологической недели. Рос журн гастроэнтерол гепатол колопроктол 1998; 8(5).
10. Полуэктова Е.А. Некоторые особенности патогенеза, клиники, диагностики и лечения больных с синдромом раздраженного кишечника: Дис. канд. мед. наук. М., 2002.
11. Полуэктова Е.А. Опыт применения дицетела при лечении больных с синдромом раздраженной кишки. Рос журн гастроэнтерол гепатол колопроктол 1999; 9(4):82-4.
12. Харкевич Д.А. Фармакология. М.: Гэотар-Медиа, 2010.
13. Шептулин А.А. Диарейный синдром. Современная классификация. Смекта в лечении диареи при синдроме раздраженной кишки. Рос журн гастроэнтерол гепатол колопроктол 1999; 9(4):86-8.
14. Andrews C.N., et al. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2011; 34(3):374-83.
15. Chey D.W. IBS: Evidence-based approach to treatment. AGA postgraduate course, May 17-18, 2003:23-6. Talley N.J. New and emerging treatment for the functional. GI disorders. AGA postgraduate course, May 18-19, 2002:35-41.
16. Clarke G., Cryan J.F., Dinan T.G., Quigley E.M. Review article: probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria. Aliment Pharmacol Ther 2012; 35:403-13.
17. Clarke G., McKernan D.P., et al. A distinct profile of tryptophan metabolism along the kynurenine pathway downstream of toll-like receptor activation in irritable bowel syndrome. Front Pharmacol 2012; 3:90.
18. Corinaldesi R., et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009; 30(3):245-52.
19. Crentsil V. Will corticosteroids and other anti-inflammatory agents be effective for diarrhea-predominant irritable bowel syndrome? Med Hypotheses 2005; 65(1):97-102.
20. Drossman D.A., McKee D.C., Sandier R.S., et al. Psychosocial factors in the irritable bowel syndrome. Gastroenterology 1988; 95:701-8.
21. Drossman D.A., Thompson W.G. I irritable bowel syndrome: a graduated, multicomponent treatment approach. Ann Intern Med 1992; 116:1009-16.
22. Floch M.H., Walker W.A., Madsen K., Sanders M.E., Macfarlane G.T., Flint H.J., Dieleman L.A., Ringel Y., Guandalini S., Kelly C.P., Brandt L.J. Recommendations for probiotic use-2011 update. J Clin Gastroenterol 2011; 45:168-71.
23. Ford A.C., Talley N.J., Schoenfeld P.S., Quigley E.M., Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58(3):367-78.
24. Holzer Р. Opioid receptors in the gastrointestinal tract. Regulatory Peptides 2009; 155(1-3):11-3.
25. Hosseini A., Nikfar S., Abdollahi M. Probiotics use to treat irritable bowel syndrome. Expert Opin Biol Ther 2012; 12:1323-34.
26. Hoveyda N., et al. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009; 9:15.
27. Ki Cha B., Mun Jung S., Hwan Choi C., et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012; 46:220-7.
28. Lee S., Kim I., Song J., et al. Clinical trial of polybutine (trimebutine maleate) in patients with irritable colon syndrome. Newcastle Med J (Seoul) 1981; 24:52-9.
29. Lüttecke K. A trial of trimebutine in spastic colon. J Int Med Res 1978; 6(2):86-8.
30. Moayyedi P., Ford A., et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59:325-32.
31. Rothstein R.D. Irritable bowel syndrome. Med Clin North Am 2000; 84(5):1247-57.
32. Ruepert L., Quartero A.O., et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. The Cochrane database of systematic reviews 2011; 8: CD003460.
33. Schaffstein W., Panijel M., Luettecke K. Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome a multicenter double blind study. Curr Ther Res 1990; 47(1):136-45.
34. Steer T., Carpenter H., Tuohy K., Gibson G.R. Perspectives on the role of the human gut microbiota and its modulation by proand prebiotics. Nutr Res Rev 2000; 13:229-54.
35. Urbanska A.M., Bhathena J., Martoni C., Prakash S. Estimation of the potential antitumor activity of microencapsulated Lactobacillus acidophilus yogurt formulation in the attenuation of tumorigenesis in Apc (Min/+) mice. Dig Dis Sci 2009; 54:264-73.
36. Whorwell P.J., Altringer L., Morel J., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101:1581-90.
37. Zhong Y.Q., et al. A randomized and case-control clinical study on trimebutine maleate in treating functional dyspepsia coexisting with diarrhea-dominant irritable bowel syndromе. Zhonghua Nei Ke Za Zhi 2007; 46(11):899-902.
Review
For citations:
Ivashkin V.T., Poluektova Ye.A., Lyashenko O.S., Reykhart D.V. Treatment of irritable bowel syndrome: the past, present and future. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2015;25(1):17-22. (In Russ.)
Views:
136
Email this article 
